心脏毒性
蒽环类
医学
重症监护医学
心肌保护
化疗
限制
药理学
癌症
内科学
乳腺癌
缺血
工程类
机械工程
作者
Pimprapa Vejpongsa,Edward T.H. Yeh
标识
DOI:10.1016/j.jacc.2014.06.1167
摘要
Anthracycline compounds are major culprits in chemotherapy-induced cardiotoxicity, which is the chief limiting factor in delivering optimal chemotherapy to cancer patients. Although extensive efforts have been devoted to identifying strategies to prevent anthracycline-induced cardiotoxicity, there is little consensus regarding the best approach. Recent advances in basic mechanisms of anthracycline-induced cardiotoxicity provided a unified theory to explain the old reactive-oxygen species hypothesis and identified topoisomerase 2β as the primary molecular target for cardioprotection. This review outlines current strategies for primary and secondary prevention of anthracycline-induced cardiotoxicity resulting from newly recognized molecular mechanisms and identifies knowledge gaps requiring further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI